|
a multicenter, international, randomized, active comparator-controlled, double-blind, doubledummy,parallel-group, 2-arm, phase 3 study to compare the efficacy and safety of the oral fxia inhibitor asundexian (bay 2433334) with apixaban for the prevention
|
25-01-202324-01-2026
|
Penyelidik Bersama
|
|
effect of modified pedometer intervention on functional status, major adverse cardiac events, and alteration in the brain network in post-covid-19 patients with cardiovascular diseases: a randomized controlled trial
|
15-01-202414-01-2026
|
Penyelidik Bersama
|
|
a randomized double-blind, placebo controlled, multicenter trial, assessing the impact of inclisiran on major adverse cardiovascular events in participants with established cardiovascular disease (victorion-2 prevent)
|
06-06-202305-06-2025
|
Penyelidik Bersama
|
|
v – good - evaluation of effectiveness and therapeutic response to vastarel 80 od® in daily practical use for chronic stable angina pectoris.
|
07-08-202306-05-2025
|
Penyelidik Bersama
|
|
investigating the cardiovascular changes in normotensive and hypertensive young adults
|
01-10-202231-03-2025
|
Penyelidik Bersama
|
|
effectiveness and impact on quality of life of a combination of trimetazidine with one hemodynamic agent (ß-blocker or ca- channel blocker), in patients recently diagnosed with stable angina and still symptomatic despite first line hemodynamic therapy:a..
|
22-06-202321-12-2024
|
Penyelidik Bersama
|
|
a phase 3,multicenter, double-blind, randomized, placebo-controlled, parallel-group study to investigate the efficacy and safety of csl112 in subjects with acute coronary syndrome(csl112_3001)
|
06-10-201805-10-2024
|
Penyelidik Bersama
|
|
the prevalence of intradialytic hypertension and its association with global longitudinal strain assessment.
|
25-03-202124-03-2024
|
Penyelidik Bersama
|